“Good cholesterol” is the common name for high-density lipoprotein cholesterol, or HDL-C, a measurement of cholesterol carried inside small, dense protein-fat particles in your blood. HDL earned its nickname decades ago when researchers noticed that people with higher levels had fewer heart attacks. But the story has grown considerably more complicated since then, and the simple idea that “more HDL is always better” no longer holds up to scrutiny.
What HDL Actually Does in Your Body
The central job that earned HDL its reputation is something researchers call reverse cholesterol transport. Cholesterol that accumulates in the walls of your arteries is a key ingredient in the fatty plaques that cause heart attacks and strokes. HDL particles act like tiny cleanup crews: they pull excess cholesterol out of cells lining your blood vessels and carry it back to the liver, where it can be broken down and excreted. The main protein on an HDL particle, apolipoprotein A-I, is the molecular key that starts this process.1PubMed Central. Apolipoprotein A1-Related Proteins and Reverse Cholesterol Transport in Antiatherosclerosis Therapy: Recent Progress and Future Perspectives
The mechanics involve a kind of relay. Specialized transporter proteins on cell surfaces hand off cholesterol to HDL particles in stages. Small, freshly made HDL particles pick up their first load of cholesterol and gradually grow into larger, rounder particles as they circulate and accumulate more.2PubMed Central. HDL and Reverse Cholesterol Transport: Basic Mechanisms and their Roles in Vascular Health and Disease Think of it like a snowball rolling downhill, gaining material as it goes, until it reaches the liver for processing.
More Than Just a Garbage Truck
Reverse cholesterol transport gets most of the attention, but HDL particles do quite a bit more. They carry antioxidant, anti-inflammatory, and anti-clotting properties that help protect the delicate lining of your blood vessels.3PubMed Central. HDL and endothelial protection One way HDL tamps down inflammation is by blocking the sticky molecules on blood vessel walls that recruit immune cells. When fewer immune cells pile into the artery wall, the inflammatory chain reaction that builds plaques slows down.4PubMed. Antiinflammatory properties of HDL
HDL also plays a role in the innate immune system. It can bind to and neutralize lipopolysaccharide, a toxic component shed by certain bacteria, reducing the body’s inflammatory reaction to infection and helping shuttle the toxin to the liver for disposal.5PubMed Central. The role of HDL in innate immunity This immune-support function may partially explain why very low HDL levels are linked to worse outcomes in critically ill patients, not just in people with heart disease.
The Framingham Evidence and Why the Number Seemed So Important
The idea that HDL-C is “good” rests heavily on large population studies, especially the Framingham Heart Study. In that landmark cohort, men with the lowest HDL-C levels (below 35 mg/dL) had roughly twice the overall death rate and nearly four times the coronary heart disease death rate compared to men with the highest levels (above 54 mg/dL), after adjusting for other risk factors. For women, the pattern held: those in the bottom group (below 45 mg/dL) had about three times the risk of dying from coronary disease compared to those in the top group (above 69 mg/dL).6PubMed. High density lipoprotein cholesterol and mortality. The Framingham Heart Study
Numbers like these, replicated across many populations, made low HDL-C a standard risk flag on blood test reports. For decades, the working assumption was straightforward: if low HDL is bad, then raising HDL must be good. That assumption turned out to be far too simple.
Why Raising HDL with Drugs Has Been a Disappointment
If higher HDL levels protect you, then a drug that pushes HDL up should prevent heart attacks. Researchers tested this idea extensively, and the results were surprising. A large meta-analysis pooling data from 39 trials and over 117,000 patients examined three different classes of HDL-raising drugs: niacin, fibrates, and CETP inhibitors. All of them successfully raised HDL-C levels. None of them reduced deaths from any cause, deaths from heart disease, heart attacks, or strokes in patients already taking statins.7PubMed Central. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
The CETP inhibitor story is particularly telling. One drug in this class, evacetrapib, more than doubled HDL-C levels in trial participants. Despite that dramatic rise, the rate of cardiovascular events was essentially identical in the drug and placebo groups, and the trial was stopped early for futility.8PubMed. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease Niacin, similarly, raised HDL-C by about 21% in a systematic review of trials but produced no meaningful drop in deaths or cardiovascular events.9PubMed. Role of Niacin in Current Clinical Practice: A Systematic Review
One CETP inhibitor, anacetrapib, did modestly reduce coronary events in a large trial, but the benefit appeared to come from its ability to lower LDL-C and non-HDL cholesterol rather than from the HDL increase itself.10PubMed Central. Trials and Tribulations of CETP Inhibitors A newer CETP inhibitor, obicetrapib, has shown potent LDL-lowering effects in early trials and is still being evaluated, but again the focus has shifted toward its impact on LDL and apolipoprotein B rather than its HDL-raising power.11PubMed Central. Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial
The pattern across all these trials pointed to the same uncomfortable conclusion: artificially inflating the HDL number on a blood test does not, by itself, make people healthier.
The Genetic Evidence Adds Another Layer of Doubt
Population studies can show that two things travel together without proving one causes the other. Genetic approaches called Mendelian randomization studies offered a way to test whether HDL-C itself causally prevents heart disease. A widely cited analysis found that genetic variants associated with lifelong higher HDL-C levels did not protect against heart attacks. A genetically driven increase of about one standard deviation in HDL-C was not linked to reduced risk of myocardial infarction.12The Lancet. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study
Another Mendelian randomization study found that when genetic variants were carefully restricted to those affecting HDL-C through a single biological pathway, the apparent protective effect of HDL-C on coronary heart disease largely disappeared.13European Heart Journal. Mendelian randomization of blood lipids for coronary heart disease More recent work suggests the relationship between HDL-C and cardiovascular disease may be nonlinear rather than absent, but the straightforward “higher is better” story has clearly broken down.14Metabolism. Nonlinear relationship between high-density lipoprotein cholesterol and cardiovascular disease: an observational and Mendelian randomization analysis
What Matters More Than the Number on Your Blood Test
If simply having a high HDL-C level does not guarantee protection, what does? Researchers have increasingly focused on what HDL particles actually do rather than how much cholesterol they carry. The most studied functional measure is cholesterol efflux capacity: how effectively a person’s HDL particles pull cholesterol out of cells.
In a landmark study, efflux capacity was a strong predictor of coronary artery disease even after adjusting for the HDL-C number on a standard blood test.15PubMed Central. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis A prospective study went further, finding that people in the highest quarter for efflux capacity had about a 67% lower risk of cardiovascular events compared to those in the lowest quarter, even after accounting for the standard HDL-C level and HDL particle concentration.16PubMed Central. HDL cholesterol efflux capacity and incident cardiovascular events Perhaps most strikingly, the inverse relationship between HDL-C level and heart disease events became statistically non-significant once efflux capacity was accounted for, suggesting that the function, not the concentration, was driving the apparent benefit all along.17PubMed Central. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study
This explains the drug failure paradox. Pumping more cholesterol into HDL particles (raising the number) is not the same as making those particles better at their job. And it explains why two people with identical HDL-C readings can have very different cardiovascular risk profiles.
When “Good” Cholesterol Goes Bad
HDL particles are not a single uniform thing. They come in a family of sizes, and their protein and lipid cargo varies considerably. Over 200 different proteins and nearly 200 lipids have been identified across the HDL population, parceled into different particle types.18PubMed Central. The Difference Between High Density Lipoprotein Subfractions and Subspecies: an Evolving Model in Cardiovascular Disease and Diabetes Large, lipid-rich HDL particles tend to track more strongly with lower cardiovascular risk in population studies, while the clinical relevance of smaller particles is less clear.19PubMed Central. HDL particle number and size as predictors of cardiovascular disease
Certain chronic diseases can transform HDL from protective to harmful. In type 2 diabetes, for example, ongoing inflammation alters the structure and composition of HDL particles so that they lose their normal anti-inflammatory, antioxidant, and cholesterol-removal functions, becoming what researchers call “dysfunctional HDL.” These altered particles may actually promote rather than prevent artery damage.20PubMed Central. Dysfunctional High-Density Lipoproteins in Type 2 Diabetes Mellitus: Molecular Mechanisms and Therapeutic Implications A study of heart attack patients found that HDL’s anti-inflammatory ability can be measured in the lab and may predict future cardiac events independently of the HDL-C number.21PubMed. The HDL anti-inflammatory function is impaired in myocardial infarction and may predict new cardiac events independent of HDL cholesterol
So “good cholesterol” is only good when it works properly. A high HDL-C reading in someone with poorly controlled diabetes or active systemic inflammation may not carry the same reassurance as the same reading in a metabolically healthy person.
The Paradox of Very High HDL
If the relationship between HDL-C and health is not a straight line going up, is there a point where too much becomes harmful? Several large studies suggest yes. A study of more than 345,000 adults found that people with HDL-C above 99 mg/dL had about a 32% higher risk of dying from any cause compared to those in the 50–59 mg/dL reference range. The excess risk was concentrated in non-cardiovascular causes of death, with cancer mortality and deaths from other causes elevated at very high HDL-C levels.22International Journal of Epidemiology. Associations between serum high-density lipoprotein cholesterol levels and cause-specific mortality in a general population of 345 000 men and women aged 20–79 years
A separate study of Korean men without diabetes found that extremely high HDL-C was associated with about a 31% higher risk of dying from any cause compared to a moderate reference group, after adjusting for other variables.23PubMed Central. Extremely high HDL cholesterol paradoxically increases the risk of all-cause mortality in non-diabetic males from the Korean population The reasons are not fully understood. Some researchers suspect that at extremely high levels, genetic variants or metabolic conditions that drive HDL up may also carry other risks. Others point to the possibility that very high HDL reflects impaired clearance rather than healthy production.
The practical takeaway is that the relationship between HDL-C and health appears U-shaped: very low and very high levels are both associated with increased mortality, with a broad middle range carrying the lowest risk.
Hormones and Sex Differences
Women tend to have higher HDL-C levels than men, largely because of estrogen’s effects on lipoprotein metabolism. Estrogen promotes HDL production and helps maintain a healthier lipid profile through several pathways, including supporting the blood vessel lining and enhancing antioxidant effects. After menopause, when estrogen drops substantially, HDL-C levels fall while LDL, triglycerides, and total cholesterol rise, contributing to the increase in cardiovascular risk that women experience in later life.24PubMed Central. A Comparative Study of Lipid Profile and Oestradiol in Pre- and Post-Menopausal Women
This hormonal influence also means that the “normal” HDL-C range differs by sex. Guideline thresholds typically consider HDL-C below 40 mg/dL in men and below 50 mg/dL in women to be low. Those numbers are not arbitrary; they reflect the biological baseline differences that estrogen creates.
How Clinical Thinking Is Shifting
The accumulated evidence from drug trials, genetic studies, and functional research has pushed cardiologists toward a major rethinking of how they use lipid numbers. Rather than fixating on raising HDL-C, current guidelines increasingly emphasize non-HDL cholesterol and apolipoprotein B as better markers of the particles that actually drive artery damage. These markers capture the total burden of cholesterol-carrying particles that deposit fat in artery walls, including LDL, VLDL, and other remnants.25PubMed Central. The Role of Non-HDL Cholesterol and Apolipoprotein B in Cardiovascular Disease: A Comprehensive Review
In practical terms, this means your doctor today is far more likely to focus on getting your LDL-C and non-HDL cholesterol down than on getting your HDL-C up. Low HDL-C is still considered a risk marker, and it still appears on standard lipid panels, but it is no longer a treatment target in the way it was in the early 2000s when niacin prescriptions were common. The shift reflects a broader lesson: a number that predicts disease is not always a number you can usefully change.
Exercise, Diet, and HDL Function
Even though drugs aimed at raising HDL-C have not panned out, lifestyle factors seem to work differently. Regular aerobic exercise does raise HDL-C modestly, and there is preliminary evidence it also improves HDL’s actual functional properties, including its antioxidant and anti-inflammatory capacity. Some research suggests a threshold of exercise intensity or duration needs to be crossed before the functional benefits appear.26PubMed Central. Effects of exercise on HDL functionality
Diet, smoking cessation, moderate alcohol intake, and weight loss all influence HDL levels and function to varying degrees. Experimental and clinical studies support the idea that these environmental factors modify how well HDL works, though the precise mechanisms are still being mapped out.27PubMed. Environmental Factors Modifying HDL Functionality The difference between lifestyle changes and drugs may come down to how the HDL is being raised. Exercise and diet tend to produce HDL particles that are genuinely better at their jobs, while drugs that artificially boost HDL-C may simply stuff existing particles with more cholesterol without improving function.
HDL in the Brain
Cholesterol management in the brain operates almost independently from the rest of the body. The blood-brain barrier blocks most plasma HDL particles from crossing into brain tissue. Instead, brain cells called glial cells produce their own HDL-like particles, and these carry apolipoprotein E rather than the apolipoprotein A-I found on blood HDL.28Cardiovascular Research. HDL and cholesterol handling in the brain Low HDL-C in the blood has been associated with cognitive impairment and neurodegenerative diseases, though the causal chain is unclear.
The apolipoprotein E story intersects with Alzheimer’s disease in a significant way. ApoE comes in three main variants in humans, and one of them, apoE4, is the strongest known genetic risk factor for late-onset Alzheimer’s. ApoE4 impairs cholesterol transport out of the brain, promotes blood-brain barrier breakdown, and increases neuroinflammation.29PubMed Central. HDL from an Alzheimer’s disease perspective While peripheral HDL-C levels and brain HDL-like particles are largely separate systems, the shared biology of apolipoproteins makes the connection between lipid metabolism and brain health a growing area of research.
HDL Across the Animal Kingdom
Humans are somewhat unusual among mammals in having LDL as their dominant circulating lipoprotein. Many other mammals, including mice, dogs, cats, and armadillos, carry most of their plasma cholesterol on HDL instead.30PubMed. Major plasma lipids and fatty acids in four HDL mammals Dogs, in particular, have especially high proportions of HDL, and veterinarians rarely see coronary artery disease in canines. This cross-species difference has long intrigued researchers. The gene that encodes endothelial lipase, a key enzyme in HDL metabolism, has been conserved across vertebrates for over 500 million years, predating the emergence of fish, which hints that the basic machinery for managing HDL-like particles is ancient and fundamental to vertebrate biology.31PubMed Central. Vertebrate endothelial lipase: comparative studies of an ancient gene and protein in vertebrate evolution
Whether humans’ reliance on LDL as a primary cholesterol carrier is a quirk of our diet, our evolutionary history, or our longevity is an open question. But the comparison with HDL-dominant animals underscores that “good cholesterol” is not just a convenient label for a blood test value. It reflects an ancient biological system that most vertebrates depend on heavily and that humans, for whatever reason, have partially sidelined.